Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVR
AVR logo

AVR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Anteris Technologies Global Corp (AVR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.780
1 Day change
2.95%
52 Week Range
10.140
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Anteris Technologies Global Corp (AVR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a slight upward trend in price and bullish moving averages, there are no significant positive catalysts, trading signals, or financial data to support a strong buy decision. The lack of recent news, neutral trading sentiment, and absence of congress trading data further suggest waiting for clearer signals or catalysts before investing.

Technical Analysis

The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD histogram is below 0 and negatively contracting, and RSI is neutral at 68.396. Key resistance levels are R1: 9.869 and R2: 10.14, with support levels at S1: 8.99 and S2: 8.719.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • Price target raised by Barclays from $17 to $18 with an Overweight rating. Enrollment in the PARADIGM pivotal trial is on track to complete by Q1 2027.

Neutral/Negative Catalysts

  • No recent news, no significant trading trends from hedge funds or insiders, and no recent congress trading data. The MACD is below 0 and negatively contracting, and the stock's historical trend suggests potential short-term declines.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Barclays maintains an Overweight rating and raised the price target to $18 from $17, indicating a positive long-term outlook.

Wall Street analysts forecast AVR stock price to rise
3 Analyst Rating
Wall Street analysts forecast AVR stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.500
sliders
Low
15
Averages
17.33
High
22
Current: 9.500
sliders
Low
15
Averages
17.33
High
22
Barclays
NULL
to
Overweight
maintain
$17 -> $18
AI Analysis
2026-05-15
Reason
Barclays
Price Target
$17 -> $18
AI Analysis
2026-05-15
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Anteris Technologies to $18 from $17 and keeps an Overweight rating on the shares. The company's Q1 results included an update on the PARADIGM pivotal trial and efforts to activate additional centers and enroll new patients in the trial, the analyst tells investors in a research note. The firm says enrollment is on track to complete by Q1 of 2027.
Cantor Fitzgerald
Overweight
initiated
$15
2026-03-12
Reason
Cantor Fitzgerald
Price Target
$15
2026-03-12
initiated
Overweight
Reason
Cantor Fitzgerald assumed coverage of Anteris Technologies with an Overweight rating and $15 price target. Anteris is positioned to capture meaningful share of the $12.4B transcatheter aortic valve replacement market for treating aortic stenosis as its differentiated TAVR platform, DurAVR, advances towards commercialization, the analyst tells investors in a research note. DurVAR could disrupt the TAVR duopoly as it has targeted unmet clinical needs, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVR
Unlock Now

People Also Watch